Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Fineline Cube May 6, 2026
Company Deals

UCB to Acquire Candid Therapeutics for $2.2B, Gaining Best-in-Class BCMA T-Cell Engager Cizutamig for Autoimmune Diseases

Fineline Cube May 6, 2026
Company Deals

SiranBio Inks $1.005B Licensing Deal with GSK for First-in-Class siRNA Therapy SA030 Targeting ALK7 in Cardiometabolic Disease

Fineline Cube May 6, 2026
Company Deals

Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam

Fineline Cube Apr 30, 2026
Company Deals

Eccogene Files Hong Kong IPO Prospectus with THR-β Agonist ECC4703 Leading Metabolic Disease Pipeline

Fineline Cube Apr 30, 2026
Policy / Regulatory

China’s NHC Establishes Regulatory Framework for Biomedical New Technologies with Interim Guiding Principles Effective May 1, 2026

Fineline Cube May 6, 2026
Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Fineline Cube May 6, 2026
Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Fineline Cube May 6, 2026
Company Deals

Jiangsu Hillgene Biopharma Secures Tens of Millions in Series A Financing for Cell Therapy R&D

Fineline Cube Apr 10, 2023

China-based cell therapy-focused Contract Development and Manufacturing Organization (CDMO) Jiangsu Hillgene Biopharma Co., Ltd has...

Company

Forecyte Bio Expands with New Cell and Gene Therapy GMP Facility in Shanghai

Fineline Cube Apr 10, 2023

Maryland-based Contract Development and Manufacturing Organization (CDMO) Forecyte Biotechnologies has announced the opening of a...

Company Drug

Yiling Pharmaceutical’s XY0206 Advances to Phase III Trial for FLT3-ITD AML

Fineline Cube Apr 10, 2023

China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced its plans to initiate a Phase...

Company Medical Device

Jiangsu Yuyue Medical Secures NMPA Approval for Semi-Automatic External Defibrillator

Fineline Cube Apr 10, 2023

Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (SHE: 002223), a China-based medical device company,...

Company Drug

MicuRx Pharmaceuticals Initiates Phase III Study for MRX-4 in Diabetic Foot Infection Treatment

Fineline Cube Apr 10, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. has announced the initiation of a Phase III clinical study...

Company Deals

AstraZeneca Partners with Guangzhou Institute to Advance Respiratory Medicine Research

Fineline Cube Apr 10, 2023

UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced a partnership with China’s Guangzhou Institute...

Company Policy / Regulatory

Indonesia and China Deepen Healthcare Ties with High-Level Dialogue and New Agreements

Fineline Cube Apr 10, 2023

Indonesia’s deputy minister of health, Dante Saksono Harbuwono, visited China last week as part of...

Policy / Regulatory

Shanxi Province Begins Historical Procurement Data Collection for Pacemaker VBP Round

Fineline Cube Apr 10, 2023

In preparation for a volume-based procurement (VBP) round, Shanxi province has initiated the gathering of...

Company Drug

TYK Medicines Secures FDA Approval for Next-Generation TKI Clinical Trial

Fineline Cube Apr 10, 2023

China-based TYK Medicines, Inc. has announced that it has received clinical trial approval from the...

Company Deals

Sequanta Technologies Partners with Element Biosciences to Expand Single-Cell Applications

Fineline Cube Apr 10, 2023

Shanghai-based Sequanta Technologies, a leading multi-omics research and clinical service provider, has announced a strategic...

Policy / Regulatory

Fujian Healthcare Security Bureau Updates Sunshine Procurement Mechanism for Drugs

Fineline Cube Apr 10, 2023

The Fujian Provincial Healthcare Security Bureau has released the Notice on Adjusting and Improving the...

Company Drug

Yifan Pharmaceutical Receives NMPA Approval for Hyruan ONE in Knee Osteoarthritis Treatment

Fineline Cube Apr 10, 2023

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) has announced receiving market approval from the National...

Company Legal / IP

Junshi Biosciences Challenges Alynlam’s PCSK9 siRNA Patent with CNIPA

Fineline Cube Apr 7, 2023

Junshi Biosciences (SHA: 688180) is reportedly taking steps to challenge a key patent held by...

Company Deals Digital

ApolloBio Partners with Baidu Health to Enhance Marketing of IgM Nano Immunoglobulin Spray

Fineline Cube Apr 7, 2023

Guangzhou-based biotech ApolloBio has signed a strategic cooperation agreement with Baidu Health. Under this partnership,...

Policy / Regulatory

China’s Provincial Governments Implement Second Batch of National Drug Use Monitoring Policy

Fineline Cube Apr 7, 2023

In line with a notification issued by the National Health Commission (NHC) in January, provincial...

Company Drug

Yantai Dongcheng Pharmaceutical Gets Singapore Regulatory Approval for 177Lu-LNC1004 Phase I Study

Fineline Cube Apr 7, 2023

China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving the green light...

Company Medical Device

AcoStream Second-Generation Receives NMPA Marketing Approval for Peripheral Vascular Use

Fineline Cube Apr 7, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced receiving marketing approval from the National...

Company Deals

Shenzhen Kangtai Biological Partners with Biotis for 13-Valent Pneumococcal Vaccine in Indonesia

Fineline Cube Apr 7, 2023

China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has struck a partnership with Indonesian...

Company Deals

Harbour BioMed and AstraZeneca Partner to Advance Pharmaceutical Innovation in Yangtze River Delta

Fineline Cube Apr 7, 2023

Harbour BioMed (HKG: 2142), a biotech with operations in the United States, the Netherlands, and...

Company Deals

Shuwen Biotech’s Subsidiary Signs Promotion Agreement with Sysmex Europe for Breast Cancer Detection Product

Fineline Cube Apr 7, 2023

China-based diagnostic specialist Shuwen Biotech Co., Ltd announced that its wholly-owned German subsidiary, Cerca Biotech...

Posts pagination

1 … 534 535 536 … 660

Recent updates

  • NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate
  • Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal
  • Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal
  • Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates
  • Senhwa Biosciences Launches Global Phase I/II Trial of First-in-Class Pidnarulex Combined with BeOne’s Tislelizumab in Solid Tumors Including Pancreatic Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate

Company Drug

Leads Biolabs’ Partner Dianthus Selects Sjögren’s, Lupus, and Dermatomyositis as Priority Indications for Bifunctional Autoimmune Drug LBL-047 Following $1B Licensing Deal

Company Drug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

Company Deals

Alebund Pharmaceuticals Files for Hong Kong IPO, Leveraging CKD-Focused Portfolio with Commercialized Mircera and Late-Stage Hyperphosphatemia Candidates

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.